JNJ

187.25

-0.16%↓

ABT

125.61

+2.29%↑

TMO

568.13

+1.65%↑

ISRG

536.58

+0.14%↑

DHR

214.86

+0.66%↑

JNJ

187.25

-0.16%↓

ABT

125.61

+2.29%↑

TMO

568.13

+1.65%↑

ISRG

536.58

+0.14%↑

DHR

214.86

+0.66%↑

JNJ

187.25

-0.16%↓

ABT

125.61

+2.29%↑

TMO

568.13

+1.65%↑

ISRG

536.58

+0.14%↑

DHR

214.86

+0.66%↑

JNJ

187.25

-0.16%↓

ABT

125.61

+2.29%↑

TMO

568.13

+1.65%↑

ISRG

536.58

+0.14%↑

DHR

214.86

+0.66%↑

JNJ

187.25

-0.16%↓

ABT

125.61

+2.29%↑

TMO

568.13

+1.65%↑

ISRG

536.58

+0.14%↑

DHR

214.86

+0.66%↑

Search

Quidel Corp

Ouvert

27.78 2.77

Résumé

Variation du prix de l'action

24h

Actuel

Min

26.51

Max

27.88

Chiffres clés

By Trading Economics

Employés

6,600

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+46.35% upside

Dividendes

By Dow Jones

Prochains Résultats

5 nov. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

300M

1.7B

Ouverture précédente

25.01

Clôture précédente

27.78

Quidel Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

3 nov. 2025, 21:44 UTC

Résultats

Vertex Pharmaceuticals Revenue Climbs on Demand for Cystic Fibrosis Drugs

3 nov. 2025, 23:44 UTC

Market Talk

Nikkei May Rise on Weaker Yen, Hopes for Govt Econ Steps -- Market Talk

3 nov. 2025, 23:34 UTC

Market Talk

Gold Edges Lower Amid Lingering Worry Over China's Ending of Tax Incentive -- Market Talk

3 nov. 2025, 23:28 UTC

Résultats

Palantir Revenue Hits Another Record as Defense Work Booms -- 2nd Update

3 nov. 2025, 23:24 UTC

Résultats

Correct: Grab Holdings Sees FY2025 Adj Ebitda $490M-$500.0M, Higher Than $460M-$480M Projected in 2Q >GRAB

3 nov. 2025, 23:14 UTC

Market Talk
Acquisitions, Fusions, Rachats

Global Equities Roundup: Market Talk

3 nov. 2025, 23:14 UTC

Market Talk
Acquisitions, Fusions, Rachats

Deterra's Next CEO Might Bring New Approach to Deals -- Market Talk

3 nov. 2025, 23:12 UTC

Résultats

Grab Holdings Sees FY2025 Adj Ebitda $490-$500.0M, Higher Than $460M-$480M Projected in 2Q >GRAB

3 nov. 2025, 23:09 UTC

Résultats

Grab Holdings 3Q 2Q Adj EBITDA $136.0M Vs. $90.0M>GRAB

3 nov. 2025, 23:09 UTC

Résultats

Grab Holdings 3Q Net $17.0M Vs. Net $15.0M >GRAB

3 nov. 2025, 23:09 UTC

Résultats

Grab Holdings 3Q Rev $873.0M Vs. $716.0M >GRAB

3 nov. 2025, 23:06 UTC

Market Talk
Résultats

Palantir Execs Forecast Future of U.S. Workers In AI World -- Market Talk

3 nov. 2025, 22:36 UTC

Market Talk
Résultats

Palantir's U.S. Commercial Business Booms as It Expands AI -- Market Talk

3 nov. 2025, 22:31 UTC

Résultats

Franco-Nevada 3Q EPS $1.49 >FNV

3 nov. 2025, 22:31 UTC

Résultats

Franco-Nevada 3Q Rev $487.7M >FNV

3 nov. 2025, 22:24 UTC

Market Talk

Xero Bulls Expect Improving U.S. Momentum in 1H -- Market Talk

3 nov. 2025, 22:19 UTC

Acquisitions, Fusions, Rachats

Starbucks Agrees to Sell Stake in China Business -- WSJ

3 nov. 2025, 21:59 UTC

Market Talk

RBA Set To Keep Rates On Hold; Remain Data Dependent -- Market Talk

3 nov. 2025, 21:54 UTC

Market Talk
Résultats

Westpac's Tech Challenge Keeps Jefferies Cautious -- Market Talk

3 nov. 2025, 21:54 UTC

Market Talk
Résultats

Global Equities Roundup: Market Talk

3 nov. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3 nov. 2025, 21:49 UTC

Résultats

Palantir Revenue Hits Another Record as Defense Work Booms -- Update

3 nov. 2025, 21:40 UTC

Résultats

Barry Diller's IAC Inks AI Deal With Microsoft. That Isn't Why the Stock Is Sliding. -- Barrons.com

3 nov. 2025, 21:31 UTC

Market Talk

Mexican Manufacturing Indexes Pick Up in October -- Market Talk

3 nov. 2025, 21:19 UTC

Résultats

Palantir Revenue Hits Another Record as Defense Work Booms -- WSJ

3 nov. 2025, 21:11 UTC

Acquisitions, Fusions, Rachats

Pfizer Reports Earnings Tuesday. Management Has Big Questions to Answer. -- Barrons.com

3 nov. 2025, 21:11 UTC

Résultats

Diamondback Energy: Increasing Full Yr Oil Production Guidance to 495-498 MBO/d and Increasing Annual BOE Guidance to 910-920 MBOE/d >FANG

3 nov. 2025, 21:07 UTC

Résultats

Palantir Technologies: Raising 2025 U.S. Comml Rev Guidance to in Excess of $1.433B, Representing a Growth Rate of at Least 104% >PLTR

3 nov. 2025, 21:05 UTC

Résultats

Vertex Pharmaceutic Sees 2025 Rev $11.9B-$12B >VRTX

3 nov. 2025, 21:05 UTC

Résultats

Palantir Technologies 3Q Net $475.6M >PLTR

Comparaison

Variation de prix

Quidel Corp prévision

Objectif de Prix

By TipRanks

46.35% hausse

Prévisions sur 12 Mois

Moyen 39.5 USD  46.35%

Haut 62 USD

Bas 26 USD

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

8 ratings

4

Achat

3

Maintien

1

Vente

Éléments financiers

$

À Propos Quidel Corp

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
help-icon Live chat